AAV Vector Delivery of AADC Gene for Parkinson's Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's Disease, particularly those involving dopamine replacement therapy, face challenges such as progressive loss of dopamine-generating cells, side effects like fluctuations in motor performance, dyskinesias, and hallucinations. There is a need for a more targeted and effective approach to restore dopaminergic function while minimizing side effects.
Innovation Solution
The use of gene therapy to deliver adeno-associated virus (AAV) vectors encoding for the aromatic L-amino acid decarboxylase (AADC) enzyme directly to the targeted regions of the central nervous system (CNS), specifically the putamen, via surgical infusion. This approach aims to increase AADC enzyme activity and thereby enhance dopamine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic administration of high-dose dopamine is used to treat Parkinson's Disease, then motor impairment is improved, but side effects such as fluctuations in motor performance, dyskinesias, and hallucinations occur
Solution Approach 1:
The patent applies local quality by using AAV vectors to deliver AADC gene specifically to the putamen region of the brain, enabling localized dopamine production rather than systemic dopamine administration. This targeted approach concentrates the therapeutic effect in the dopaminergic pathways of the putamen while avoiding widespread dopaminergic stimulation that causes side effects.
Solution Approach 2:
The patent uses AADC enzyme as an intermediary - instead of administering dopamine directly, the therapy delivers the AADC gene which enables endogenous conversion of L-DOPA to dopamine within the putamen. This intermediary approach allows controlled local dopamine synthesis from the more tolerable L-DOPA precursor, reducing the harmful effects of high-dose exogenous dopamine.
2Object-generated harmful factors
If gene therapy with AAV vectors encoding AADC is used to restore dopaminergic function, then side effects are minimized, but the complexity of the treatment approach increases
Solution Approach 1:
The patent implements self-service by delivering the AADC gene itself rather than the enzyme or dopamine. The introduced gene enables patient cells to autonomously produce AADC enzyme and convert L-DOPA to dopamine locally, creating a self-sustaining therapeutic mechanism that reduces side effects while the one-time surgical infusion simplifies long-term treatment complexity.
3Manufacturing precision
If AAV vectors are delivered via surgical infusion to the putamen, then targeted dopamine production is achieved, but the invasiveness of the procedure increases
Solution Approach 1:
The patent applies segmentation by dividing the AAV vector into separate components (capsid protein and genome) that are produced independently and then assembled. This modular approach allows optimization of each component for targeted delivery to the putamen while minimizing surgical invasiveness through standardized vector construction and infusion protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of AAV vectors encoding AADC results in a therapeutically effective outcome, including a significant increase in AADC enzyme activity, reduction in Unified Parkinson's Disease Rating Scale (UPDRS) III scores, and improvement in diary ON-time without troublesome dyskinesia, leading to better motor function and quality of life for patients.
Implementation Method 1
One strategy to restore dopaminergic function and minimize side effects is the use of gene therapy to deliver AADC directly to a targeted region of the CNS
Implementation Method 2
The adeno-associated virus (AAV) has emerged as an attractive vector for gene therapy due to its long-term gene expression, the inability to autonomously replicate without a helper virus, the ability to transduce dividing and non-dividing cells
Implementation Method 3
Aromatic L-amino acid decarboxylase (AADC) is a homodimeric pyridoxal phosphate-dependent enzyme responsible for the synthesis of dopamine and serotonin. The encoded protein catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (L-DOPA or levodopa) to dopamine
Data Source
AI summary
The present disclosure relates to methods, formulations and devices for the delivery and therapeutic administration of polynucleotides encoding AADC. The present disclosure relates to methods, formulations and devices for the delivery and therapeutic administration of AAV vectors which include polynucleotides encoding AADC. The present disclosure relates to methods, formulations and devices for the delivery and therapeutic administration of polynucleotides encoding AADC in the treatment of neurological diseases, disorders and conditions, including Parkinson's Disease.